EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of rapid molecular testing on clinical outcomes for methicillin-susceptible Staphylococcus aureus bacteremia

Jay Olivet iD, Matthew L Brown iD, Megan Amerson-Brown iD, W Seth Edwards iD, Robert A Oster iD, Joshua Stripling iD

Antimicrobial Stewardship & Healthcare Epidemiology · 2026 · 6 (1)

DOI: 10.1017/ash.2026.10749 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Stewardship & Healthcare Epidemiology, online erschienen am 24.06.2026. Verfasst von Jay Olivet und 5 weiteren Autor:innen. Beteiligte Einrichtung: UAB Hospital, Birmingham, USA. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rapid molecular blood culture identification (BCID) enables earlier pathogen identification and targeted antibiotic therapy compared with traditional culture-based methods. Methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia is optimally treated with anti-staphylococcal β-lactam antibiotics; however, delays in bacterial identification frequently result in prolonged empiric anti-methicillin-resistant Staphylococcus aureus (MRSA) therapy. Data evaluating the clinical impact of early MSSA identification remain limited.

Methods

This retrospective, single-center, quasi-experimental program evaluation included adult patients with monomicrobial MSSA bacteremia. Patients were grouped based on identification by BCID or conventional culture-based methods. Automatic Infectious Diseases consultation was performed for all patients. The primary outcome was a desirability of outcome ranking incorporating treatment success, acute kidney injury (AKI), and inpatient mortality. Secondary outcomes included time-to-optimal therapy, duration of bacteremia, treatment success, and hospital length of stay.

Results

A total of 300 patients were included (150 per cohort). BCID use was associated with earlier MSSA identification (0.8 vs 2.1 days; P < .001) and earlier initiation of targeted β-lactam therapy (1.9 vs 3.8 days; P < .001). The probability of a more desirable outcome with BCID was 58.5% (95% CI: 52.5% to 64.3%), and more individuals achieved the most desirable outcome (62.0% vs 46.0%; P = .005). AKI occurred less frequently in the BCID group (23.5% vs 44.2%; P < .001).

Conclusions

Incorporation of rapid BCID into an established automatic Infectious Diseases consultation program improved outcomes in MSSA bacteremia by facilitating earlier β-lactam therapy and reducing nephrotoxicity. Antimicrobial stewardship programs should prioritize rapid diagnostics to optimize MSSA management.

Autor:innen und Institutionen

  • UAB Hospital, Birmingham, USA.
  • UAB Medicine: UAB Health System, USA.

ORCID-Profile: Jay Olivet, Matthew L Brown, Megan Amerson-Brown, W Seth Edwards, Robert A Oster, Joshua Stripling

Zitieren

APA

Olivet, J., Brown, M. L., Amerson-Brown, M., Edwards, W. S., Oster, R. A., & Stripling, J. (2026). Impact of rapid molecular testing on clinical outcomes for methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrobial Stewardship & Healthcare Epidemiology, 6(1). https://doi.org/10.1017/ash.2026.10749

Vancouver

Olivet J, Brown ML, Amerson-Brown M, Edwards WS, Oster RA, Stripling J. Impact of rapid molecular testing on clinical outcomes for methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrobial Stewardship & Healthcare Epidemiology. 2026;6(1). doi:10.1017/ash.2026.10749

BibTeX
@article{Olivet2026,
  author = {Olivet, Jay and Brown, Matthew L and Amerson-Brown, Megan and Edwards, W Seth and Oster, Robert A and Stripling, Joshua},
  title = {Impact of rapid molecular testing on clinical outcomes for methicillin-susceptible Staphylococcus aureus bacteremia},
  journal = {Antimicrobial Stewardship & Healthcare Epidemiology},
  year = {2026},
  volume = {6},
  number = {1},
  doi = {10.1017/ash.2026.10749}
}
Kostenlos starten →